<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">IJPharm</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0253-7613</issn>
      <issn pub-type="epub">1998-3751</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24550600</article-id>
      <article-id pub-id-type="pmc">3912798</article-id>
      <article-id pub-id-type="publisher-id">IJPharm-46-125</article-id>
      <article-id pub-id-type="doi">10.4103/0253-7613.125195</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Drug Watch</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>&#x15E;endur</surname>
            <given-names>Mehmet A. N.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aksoy</surname>
            <given-names>Sercan</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>&#xD6;zdemir</surname>
            <given-names>Nuriye Y&#x131;ld&#x131;r&#x131;m</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zengin</surname>
            <given-names>Nurullah</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey</aff>
      <aff id="aff2"><label>1</label>Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey</aff>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence to:</bold> Dr. Mehmet A. N. &#x15E;endur, E-mail: <email xlink:href="masendur@yahoo.com.tr">masendur@yahoo.com.tr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2014</year>
      </pub-date>
      <volume>46</volume>
      <issue>1</issue>
      <fpage>125</fpage>
      <lpage>126</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>03</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>08</day>
          <month>12</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Pharmacology</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.</p>
      </abstract>
      <kwd-group>
        <title>KEY WORDS</title>
        <kwd>Adverse drug reactions</kwd>
        <kwd>bevacizumab</kwd>
        <kwd>colorectal cancer</kwd>
        <kwd>necrotizing fasciitis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1-1">
      <title>Introduction</title>
      <p>Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor. The addition of bevacizumab to first or second line chemotherapy was associated with longer overall survival (OS) and progression free survival (PFS) in metastatic colorectal patients. The adverse events associated with bevacizumab include hypertension, proteinuria, thromboembolism, impaired wound healing, bleeding, perforation, reversible leukoencephalopathy syndrome, skin rash, and infusion-related hypersensitivity reactions.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref>] We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer.</p>
    </sec>
    <sec id="sec1-2">
      <title>Case Report</title>
      <p>A 49-year-old man was admitted to clinic with rectal bleeding. Low anterior resection with ileostomy was performed for rectal mass 5 cm from anus. According to the tumor, node, metastases classification, the pathological stage of the carcinoma was T3N1M0 (stage IIIA). The patient was treated with adjuvant 45 Gy chemoradiotherapy with 5-fluorouracil 225 mg/m<sup>2</sup> daily and then fluorouracil-leucovorin-oxaliplatin (FOLFOX4) regimen. After two cycles of FOLFOX4 regimen, serum carcinoembryonic antigen levels had increased. In the radiologic evaluation with chest and abdominal computed tomography, new liver metastases in both lobes were detected. The hepatic metastases were unresectable, hence the patient shifted to regimen of 5-fluorouracil-leucovorin-irinotecan (FOLFIRI). After 12 courses of the FOLFIRI regimen every 2 weeks, the chemotherapy was stopped due to the stable liver metastases. Because of the new metastatic lesions in the liver and pelvic recurrence, bevacizumab added to FOLFIRI regimen. After 10 days of the third cycle of the FOLFIRI-bevacizumab regimen, the patient was admitted with fever, weakness, abdominal pain and erythema of the proximal side of right thigh. The laboratory evaluation revealed a white blood cell count of 22.000/&#x3BC;l (normal value 4,400-11,000/&#x3BC;l) with increased C-reactive protein to 160 mg/l (normal value: 0-10 mg/l). The magnetic resonance imaging (MRI) of the pelvis showed widespread significant air-fluid level abscess in the tissues of right gluteus maximus, gluteus minimus and vastus muscles. A clinical diagnosis of necrotizing fasciitis was made. Ultrasonography-guided drainage of the abscess was performed and 10F pigtail catheter was inserted to the abscess location. The microbiological culture of the material was revealed vancomycin-resistant enterococcus (VRE), <italic>Escherichia coli</italic>, and <italic>Bacteroides fragilis</italic>. The patient was treated with linezolid, imipenem, and metronidazole. Patient responded to treatment for initial few days, but on the 7<sup>th</sup> day of the antibiotic treatment, acute renal failure and septic shock was developed. The patient died due to the refractory septic shock.</p>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>Discussion</title>
      <p>Necrotizing fasciitis is an uncommon severe soft tissue infection involving the subcutaneous fat and fascia. There are an estimated 3.5 cases of necrotizing fasciitis per 100,000 persons, with a case-fatality rate of 24% despite immediate treatment.[<xref rid="ref3" ref-type="bibr">3</xref>] Approximately of the 60-70% of cases are polymicrobial. Severe and acute onset of the pain at the infectious site is the most common clinical presentation. The risk factors of necrotizing fasciitis are diabetes mellitus, malnutrion, trauma, operative interventions, and nonsteroidal anti-inflammatory drugs (NSA&#x130;Ds) usage.[<xref rid="ref4" ref-type="bibr">4</xref>] Rarely, necrotizing fasciitis can develop due to all-trans-retinoic acid, bisphosphonates, and radiotherapy.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] In addition, necrotizing fasciitis has also been reported in renal transplant recipient who treated with FK506.[<xref rid="ref8" ref-type="bibr">8</xref>]</p>
      <p>Serious adverse events with bevacizumab treatment were hemorrhage, gastrointestinal perforation, and arterial thromboembolic events. Arterial thromboemebolic events were seen between 1 and 2% of patients during bevacizumab treatment.[<xref rid="ref9" ref-type="bibr">9</xref>] One of the pathophysiologic mechanism of necrotizing fasciitis is subcutaneous arteries thrombosis and tissue ischemia, bevacizumab can be the etiologic factor for this.[<xref rid="ref10" ref-type="bibr">10</xref>] The Naranjo probability score revealed that it was probable (+5) that bevacizumab might be responsible for necrotizing fasciitis. We believe that in our patient, necrotizing fasciitis is due to bevacizumab treatment because there was no additional risk factor and there is temporal relationship between necrotizing fasciitis and bevacizumab treatment.</p>
      <p>In conclusion, we presented fatal necrotizing fasciitis in a patient during bevacizumab treatment for rectal cancer. Although precise mechanism is not clear, necrotizing fasciitis is a fulminant disease and can be observed during bevacizumab treatment.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict of Interest:</bold> None declared</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kabbinavar</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Hambleton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mass</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Hurwitz</surname>
              <given-names>HI</given-names>
            </name>
            <name>
              <surname>Bergsland</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sarkar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>3706</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="pmid">15867200</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hurwitz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fehrenbacher</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Novotny</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Cartwright</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hainsworth</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Heim</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>2335</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">15175435</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O&#x2019;Loughlin</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Roberson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cieslak</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Lynfield</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gershman</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Craig</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004</article-title>
          <source>Clin Infect Dis</source>
          <year>2007</year>
          <volume>45</volume>
          <fpage>853</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="pmid">17806049</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sehgal</surname>
              <given-names>VN</given-names>
            </name>
            <name>
              <surname>Sehgal</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Sehgal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Khandpur</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Necrotizing fasciitis</article-title>
          <source>J Dermatolog Treat</source>
          <year>2006</year>
          <volume>17</volume>
          <fpage>184</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">16854763</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naithani</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mahapatra</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Fournier's gangrene and scrotal ulcerations during all-trans-retinoic acid therapy for acute promyelocytic leukemia</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2008</year>
          <volume>5</volume>
          <fpage>303</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">18421710</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Livengood</surname>
              <given-names>CH</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Soper</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Clarke-Pearson</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Addison</surname>
              <given-names>WA</given-names>
            </name>
          </person-group>
          <article-title>Necrotizing fasciitis in irradiated tissue from diabetic women. A report of two cases</article-title>
          <source>J Reprod Med</source>
          <year>1991</year>
          <volume>36</volume>
          <fpage>455</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">1865403</pub-id>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Setabutr</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hales</surname>
              <given-names>NW</given-names>
            </name>
            <name>
              <surname>Krempl</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
          <article-title>Necrotizing fasciitis secondary to bisphosphonate-induced osteonecrosis of the jaw</article-title>
          <source>Am J Otolaryngol</source>
          <year>2010</year>
          <volume>3</volume>
          <fpage>127</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">20015718</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kwok</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>KN</given-names>
            </name>
          </person-group>
          <article-title>Necrotizing fasciitis in a renal transplant recipient treated with FK 506: The first reported case</article-title>
          <source>Clin Nephrol</source>
          <year>2001</year>
          <volume>56</volume>
          <fpage>481</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">11770800</pub-id>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hompes</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ruers</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer</article-title>
          <source>Eur J Surg Oncol</source>
          <year>2011</year>
          <volume>37</volume>
          <fpage>737</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">21764243</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarani</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Strong</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pascual</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schwab</surname>
              <given-names>CW</given-names>
            </name>
          </person-group>
          <article-title>Necrotizing fasciitis: Current concepts and review of the literature</article-title>
          <source>J Am Coll Surg</source>
          <year>2009</year>
          <volume>208</volume>
          <fpage>279</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">19228540</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
